Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today

Alnylam Pharmaceuticals (ALNY) stock rose 6.9% after the company shared positive long-term data for AMVUTTRA, reinforcing its cardiovascular benefits. The company also reiterated 2026 guidance and authorized a $1 billion share repurchase program, signaling confidence. Insider and institutional trading activity was noted, with mixed positions.

Original reporting
Published Nov 13, 2026, 3:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today — source image
Decision brief

The 30-second read

$ALNYBullishHigh
01

Why it matters

The data addresses a key efficacy endpoint, likely improving market perception and supporting the stock's recent rally.

02

Market read

The announcement provides fresh, material information that directly moves ALNY's price, making it a high‑impact trading signal.

03

What to watch

Potential regulatory review timeline and reimbursement uncertainty could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Alnylam announced new long‑term data from its HELIOS‑B trial for AMVUTTRA in ATTR‑CM and a $1 bn share repurchase program.

Company-level read

Ticker impact

$ALNYBullishHigh confidence
Context

ALNY jumped 6.9% as new five‑year HELIOS‑B data showed mortality benefit for AMVUTTRA and the board announced a $1 bn share repurchase.

Expected impact

upward bias as investors price in durable cardiovascular benefit and undervaluation perception.

Evidence & confidence

Clinical data is a material catalyst for a biotech; combined with a sizable repurchase program it supports further upside.

Market effects

Strengthens outlook for the rare‑disease and cardiovascular biotech subsectors.

Positive for US biotech equities, modest spillover to related pharma stocks.

Limited to investors focused on biotech and specialty pharma.

Counterpoint

Skeptics may question durability of mortality benefit and potential pricing pressure from upcoming competition.

Key entities

  • Alnylam Pharmaceuticals

    US‑listed biotech developing RNAi therapies.

Related articles

$ALNYMedAI 9/10

Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CM

Alnylam Pharmaceuticals (ALNY) reported five-year data from the HELIOS-B study, showing that early treatment with AMVUTTRA (vutrisiran) in ATTR-CM patients led to better long-term outcomes, including a 48% reduction in mortality and cardiovascular events in the monotherapy group. The study also showed improved quality of life and stability in cardiac biomarkers. The safety profile remained consistent. The findings were presented at the American Heart Association Scientific Sessions 2026.